Dr. Roberto Rosa
Buenos Aires, Argentina
NCT Number: NCT01080014
This observational study is being conducted to evaluate the usefulness of the MSFC and its relationship with EDSS scores in subjects with MS in Argentina.
Looking for future studies?
Notify Me18 year–65 year
All sexes
Observational
Buenos Aires, Argentina
This observational, open-label study is being conducted to correlate change in EDSS score with the change in MSFC scores at the end of a 2-year follow-up period for subjects with MS in Argentina. Measurement of disability is an indispensable parameter in assessing the efficacy of experimental therapeutic agents in MS as well as in trying to determine possible individual evolution of the disease. Clinical scales are being used as primary or secondary outcome measures for recording disease progression in clinical trials. Kurtzke's EDSS is still used as a gold standard for measuring impairment and disability in MS. The MSFC is an examination-based quantitative scoring of neurological impairment. This study aims to establish a correlation between the usefulness of both scales.
OBJECTIVES
Primary Objective:
Secondary Objectives:
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: Baseline and two years
Time frame: Baseline, 1 year, 2 years
Merck KGaA, Darmstadt, Germany
Industry
The Multiple Sclerosis Functional Composite (MSFC) in the Follow-up of MS Patients: Correlation With the Expanded Disability Status Scale (EDSS) Among Different Clinical Forms in Argentina
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07680738
Autoimmune Diseases, Autoimmune Diseases of the Nervous System
Mexico City, Mexico
View Trial DetailsNCT05168384
Autoimmune Diseases, Autoimmune Diseases of the Nervous System
Abu Dhabi, Abu Dhabi Emirate, United Arab Emirates
View Trial DetailsNCT04289909
Autoimmune Diseases, Autoimmune Diseases of the Nervous System
Paris, France
View Trial DetailsNCT04201470
Autoimmune Diseases, Autoimmune Diseases of the Nervous System
Montpellier, France
View Trial Details